Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Allarity Therapeutics, Inc. - Common stock (NQ:ALLR)

0.9900 +0.0300 (+3.13%)
Streaming Delayed Price Updated: 4:00 PM EDT, Mar 21, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 2,473,927
Open 0.9400
Bid (Size) 1.060 (6)
Ask (Size) 1.080 (64)
Prev. Close 0.9600
Today's Range 0.9003 - 1.050
52wk Range 0.6775 - 214.56
Shares Outstanding 198,742,643
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Allarity Therapeutics Announces Presentation of Phase 2 Clinical Data from Ongoing Trial in Advanced Ovarian Cancer Patients at the 2025 Annual Meeting for the Society of Gynecologic Oncology
From Allarity Therapeutics, Inc.
Via GlobeNewswire
Allarity Therapeutics Announces Final Settlement with the U.S. Securities and Exchange Commission
From Allarity Therapeutics, Inc.
Via GlobeNewswire

Performance

YTD
-10.8%
-10.8%
1 Month
+5.9%
+5.9%
3 Month
-0.0%
-0.0%
6 Month
-55.2%
-55.2%
1 Year
-99.5%
-99.5%

More News

Read More
ReShape Lifesciences, Allarity, Exact Sciences, CVS, AbbVie: 5 Health Care Stocks That Led Retail Message Growth Last Week
Via Stocktwits
Allarity Therapeutics Announces Phase 2 Trial of Stenoparib in Combination with Temozolomide for Recurrent Small Cell Lung Cancer Fully Funded by the US Veterans Administration
From Allarity Therapeutics, Inc.
Via GlobeNewswire
Allarity Therapeutics Announces Board Authorization of $5 Million Share Repurchase Program
From Allarity Therapeutics, Inc.
Via GlobeNewswire
Allarity Therapeutics Announces Dismissal of Securities Class Action Lawsuit
From Allarity Therapeutics, Inc.
Via GlobeNewswire
Allarity Therapeutics to Begin Enrollment for New Phase 2 Protocol to Advance Stenoparib Toward FDA Approval in Advanced Ovarian Cancer Patients
From Allarity Therapeutics, Inc.
Via GlobeNewswire
Allarity Therapeutics Announces Expansion of Phase 2 Clinical Trial to Accelerate Development of Stenoparib in Advanced Ovarian Cancer
From Allarity Therapeutics, Inc.
Via GlobeNewswire
Allarity Therapeutics Announces Filing of Form 8-K Regarding Settlement Agreement in Principle with SEC
From Allarity Therapeutics, Inc.
Via GlobeNewswire
Allarity Therapeutics Reports Key Progress in Phase 2 Stenoparib Trial and Strategic Corporate Advancements
From Allarity Therapeutics, Inc.
Via GlobeNewswire
Allarity Therapeutics Reports Third Quarter 2024 Financial Results and Provides Recent Operational Highlights
From Allarity Therapeutics, Inc.
Via GlobeNewswire
ALLR Investors Have Opportunity to Lead Allarity Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm
From The Schall Law Firm
Via Business Wire
FINAL DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Allarity Therapeutics
From Faruqi & Faruqi, LLP
Via Business Wire
ALLR DEADLINE: ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Allarity Therapeutics, Inc. Investors With Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action – ALLR
From The Rosen Law Firm PA
Via GlobeNewswire
ALLR Deadline: Rosen Law Firm Urges Allarity Therapeutics, Inc. (NASDAQ: ALLR) Stockholders with Large Losses to Contact the Firm for Information About Their Rights
From The Rosen Law Firm, P.A.
Via Business Wire
The Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Allarity Therapeutics, Inc. (ALLR)
From The Law Offices of Frank R. Cruz
Via Business Wire
DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Allarity Therapeutics
From Faruqi & Faruqi LLP
Via GlobeNewswire
ALLARITY ALERT: Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Filed Against Allarity Therapeutics, Inc. and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors of Allarity Therapeutics to Contact Us to Have Their Losses Evaluated Today
From Faruqi & Faruqi LLP
Via GlobeNewswire
INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Allarity Therapeutics
From Faruqi & Faruqi LLP
Via GlobeNewswire
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against GitLab, Allarity, ZoomInfo, and Agenus and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
ROSEN, NATIONAL INVESTOR COUNSEL, Encourages Allarity Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – ALLR
From The Rosen Law Firm PA
Via GlobeNewswire
ROSEN, NATIONAL INVESTOR COUNSEL, Encourages Allarity Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – ALLR
From The Rosen Law Firm PA
Via GlobeNewswire
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Allarity, Metagenomi, Agenus, and New Fortress and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
Allarity Therapeutics to be Granted European Patent for DRP® Companion Diagnostic for Stenoparib
From Allarity Therapeutics, Inc.
Via GlobeNewswire

Frequently Asked Questions

Is Allarity Therapeutics, Inc. - Common stock publicly traded?
Yes, Allarity Therapeutics, Inc. - Common stock is publicly traded.
What exchange does Allarity Therapeutics, Inc. - Common stock trade on?
Allarity Therapeutics, Inc. - Common stock trades on the Nasdaq Stock Market
What is the ticker symbol for Allarity Therapeutics, Inc. - Common stock?
The ticker symbol for Allarity Therapeutics, Inc. - Common stock is ALLR on the Nasdaq Stock Market
What is the current price of Allarity Therapeutics, Inc. - Common stock?
The current price of Allarity Therapeutics, Inc. - Common stock is 0.9900
When was Allarity Therapeutics, Inc. - Common stock last traded?
The last trade of Allarity Therapeutics, Inc. - Common stock was at 03/21/25 04:00 PM ET
What is the market capitalization of Allarity Therapeutics, Inc. - Common stock?
The market capitalization of Allarity Therapeutics, Inc. - Common stock is 196.76M
How many shares of Allarity Therapeutics, Inc. - Common stock are outstanding?
Allarity Therapeutics, Inc. - Common stock has 197M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.